Colin Rutherford Net Worth

Colin Rutherford biography

Colin Rutherford serves as Independent Director of the Company. He joined the Board of a Spanish Biopharma business, Hifas da Terra SA, in 2018, which is a leading product innovator in the field of mycotherapy, providing applications for use in both immunotherapy and oncology. Since 2013, he has served on the Board and is Audit Committee Chairman of Mitchells & Butlers Plc, the UK’s largest quoted F&B leisure group. Since 2005, he has served on the Board and Audit Committee of the quoted Oil & Gas shipping logistics business, Renaissance Services SAOG, based in Muscat and Dubai. He has been the Chairman of Brookgate Limited, a UK property development business backed by Goldman Sachs and TPG. Mr. Rutherford also serves as Executive Chairman of Teachers Media plc, a private education company. Mr. Rutherford serves independently on three private Scottish based family company Boards in Healthcare, Retail and Timber. From 2012 to 2014, Mr. Rutherford served as Chairman of European Healthcare Group Limited, before its acquisition by two US based hedge funds. From 2008 to 2011, Mr. Rutherford served as Chairman and CEO of the quoted UK fund management group, MAM Funds Plc. From 2004 to 2009, Mr. Rutherford served as Chairman of SGI Funds, a Guernsey, Cayman and Hong Kong based diversified fund management group. From 2003 to 2006 Mr. Rutherford was Chairman and oversaw the restructuring of Noble House Group Limited, a large UK leisure business which was sold in 2006. In 2002 as Chairman and CEO he led the restructuring and sale of quoted UK finance specialist Euro-Sales Plc with 18 offices across Europe. Mr. Rutherford graduated in Accountancy and Finance from Heriot Watt University and qualified as a chartered accountant with Touche Ross in 1984. Mr. Rutherford is a Harvard Business School Alumni. Rutherford is qualified to serve as a member of our Board of Directors because of his prior experience as a member of Private Evofem’s Board of Directors and his many years of finance and operations l

What is the salary of Colin Rutherford?

As the Independent Director of Evofem Biosciences Inc, the total compensation of Colin Rutherford at Evofem Biosciences Inc is $254,900. There are 10 executives at Evofem Biosciences Inc getting paid more, with Saundra Pelletier having the highest compensation of $2,803,980.

How old is Colin Rutherford?

Colin Rutherford is 61, he's been the Independent Director of Evofem Biosciences Inc since 2018. There are 3 older and 10 younger executives at Evofem Biosciences Inc. The oldest executive at Evofem Biosciences Inc is Gillian Greer, 75, who is the Independent Director.

What's Colin Rutherford's mailing address?

Colin's mailing address filed with the SEC is C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA, 92130.

Insiders trading at Evofem Biosciences Inc

Over the last 7 years, insiders at Evofem Biosciences Inc have traded over $32,368,585 worth of Evofem Biosciences Inc stock and bought 12,978,479 units worth $54,857,186 . The most active insiders traders include Research Corp Acacia, Fund Solutions Ltd Link und Biopharma, Inc. Pdl. On average, Evofem Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $5,281. The most recent stock trade was executed by Yan Zhang on 12 January 2024, trading 104 units of EVFM stock currently worth $4.

What does Evofem Biosciences Inc do?

evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.

Evofem Biosciences Inc executives and stock owners

Evofem Biosciences Inc executives and other stock owners filed with the SEC include:

• Saundra Pelletier,
  President, Chief Executive Officer, Director
• Kelly Culwell,
  Chief Medical Officer
• Saundra Pelletier,
  Pres, CEO & Director
• Thomas Lynch,
  Chairman of the Board
• Russell Barrans,
  Chief Commercial Officer
• Justin File,
  Chief Financial Officer
• Justin J. File,
  Chief Financial Officer
• Russell Barrans,
  Chief Commercial Officer
• Tony O'Brien,
  Independent Director
• William Hall,
  Independent Director
• Colin Rutherford,
  Independent Director
• Gillian Greer,
  Independent Director
• Kim Kamdar,
  Independent Director
• Amy Raskopf,
  IR Contact Officer
• Lisa Rarick,
  Independent Director
• Alexander Fitzpatrick,
  Executive Vice President, General Counsel, Secretary
• Dr. Kelly Culwell M.D.,
  Chief Medical Officer
• Kathy Gallo-Doyle,
  VP of Sales
• Alexander A. Fitzpatrick Esq.,
  Exec. VP, Gen. Counsel & Sec.
• Biopharma, Inc. Pdl,
  10% owner
• Research Corp Acacia,
  10% owner
• Anthony Stephen O'brien,
  Director
• Yan Zhang,
  CFO
• Ltd. Invesco,
  10% owner
• Fund Solutions Ltd Link,
  10% owner